Table 1.
Baseline characteristics of infants by randomized treatment group, stratified by HIV infection statusa
| Infant characteristic | HIV-infected infants (n = 35) given: |
HIV-exposed infants (n = 201) given: |
||
|---|---|---|---|---|
| Multivitamin | Placebo | Multivitamin | Placebo | |
| n | 17 | 18 | 101 | 100 |
| Female | 9 (52.9) | 7 (38.9) | 49 (48.5) | 48 (48.0) |
| Age at vaccination | ||||
| 8.5–10 mo | 6 (35.3)b | 13 (72.2)b | 60 (59.4) | 54 (54.0) |
| 10–11 mo | 10 (58.8)b | 4 (22.2)b | 32 (31.7) | 32 (32.0) |
| 11–12 mo | 1 (5.8)b | 1 (5.6)b | 9 (8.9) | 14 (14.0) |
| Any breastfeeding at: | ||||
| 6 mo | 6 (41.2) | 7 (38.9) | 26 (25.7) | 26 (26.0) |
| 8 mo | 2 (11.8) | 0 (0.0) | 9 (8.9) | 5 (5.0) |
| Time of vaccination | 0 (0.0) | 0 (0.0) | 3 (2.9) | 1 (1.0) |
| Nutritional status at vaccination | ||||
| Stunting | 9 (52.9) | 7 (38.9) | 11 (10.9) | 15 (15.0) |
| Wasting | 4 (23.5) | 4 (22.2) | 13(12.9) | 15 (15.0) |
| Underweight | 8 (47.1) | 8 (44.4) | 14 (13.9) | 20 (20.0) |
| Receiving ARTc | 3 (17.6) | 6 (33.3) | ||
| Maternal CD4 T-cell count at randomization (cells/μl) | ||||
| <200 | 2 (11.8) | 1 (5.6) | 12 (11.9) | 6 (6.0) |
| 200–350 | 7 (41.2) | 7 (38.9) | 13 (12.9) | 18 (18.0) |
| >350 | 6 (35.3) | 9 (50.0) | 66 (65.3) | 67 (67.0) |
| Data missing | 2 (11.8) | 1 (5.6) | 10 (9.9) | 9 (9.0) |
| Mother received HAART during pregnancy | 4 (23.5) | 6 (33.3) | 26 (25.7) | 15 (15.0) |
a
Data are presented as no. (%).
b
P < 0.10.
c
ART, antiretroviral therapy.